Diagnosis and Treatment of Parkinson's Disease

Diagnostic Criteria

• The American College of Radiology recommends that the diagnosis of Parkinson's disease (PD) is primarily clinical, based on the cardinal motor signs of bradykinesia plus either resting tremor, rigidity, or both, with MRI brain imaging and I-123 ioflupane SPECT/CT serving as supportive diagnostic tools when clinical presentation is unclear 1, 2, 3
• Bradykinesia (slowness of movement) is the essential diagnostic feature, accompanied by at least one of the following cardinal signs: resting tremor, rigidity, or postural instability (though postural instability typically appears later in disease progression) 1, 2
• Symptoms typically appear after approximately 40-50% of dopaminergic neurons in the substantia nigra have been lost, usually about 5 years after the initial neurodegeneration begins 1

Diagnostic Imaging

• MRI brain without contrast is the optimal imaging modality when structural causes need to be ruled out, though it is often normal in early PD 3, 4
• I-123 ioflupane SPECT/CT (DaTscan) is valuable for differentiating PD from essential tremor or drug-induced tremor, showing decreased radiotracer uptake in the striatum (usually beginning in the putamen and progressing to caudate) 5, 6
• A normal I-123 ioflupane SPECT/CT essentially excludes Parkinsonian syndromes 5
• CT has limited utility due to poor soft tissue contrast but can help exclude structural lesions or vascular disease 7

Differential Diagnosis

• PD must be differentiated from other Parkinsonian syndromes, including progressive supranuclear palsy (PSP) 5, multiple system atrophy (MSA) 7, corticobasal degeneration (CBD) 7, and vascular parkinsonism 1, 2
• Red flags suggesting diagnoses other than PD include ataxia 7

Diagnostic Criteria and Red Flags for Parkinsonism

Clinical Features and Diagnostic Testing

• Vertical gaze palsy, especially downward, suggests Progressive Supranuclear Palsy (PSP), according to the Brain journal 8, 9
• Asymmetric rigidity with alien hand phenomenon suggests Corticobasal Syndrome, as reported in the Brain journal 8, 9

Bradykinesia: Clinical Characteristics and Treatment

Motor Symptoms

• Bradykinesia can affect all voluntary movements, including fine motor tasks, such as buttoning clothes or writing, gross motor activities, like walking or turning, facial expressions, and speech, according to the American Academy of Child and Adolescent Psychiatry 10
• Drug-induced parkinsonism, which can cause bradykinesia, must be distinguished from other parkinsonian syndromes and negative symptoms in psychiatric disorders, as noted by the American Academy of Child and Adolescent Psychiatry 10, 11
• Anticholinergic or mild dopaminergic agents, such as amantadine, are used to treat drug-induced parkinsonism symptoms, including bradykinesia, as recommended by the American Academy of Child and Adolescent Psychiatry 10, 11

Assessment of Rigidity in Patients with Bradykinesia

Proper Technique for Assessing Rigidity

• To assess rigidity in a patient with bradykinesia, passively move the patient's limbs while instructing them to relax, and assess resistance to movement throughout the range of motion, noting any cogwheel phenomenon that may occur when rigidity is combined with tremor 12
• Rigidity is one of the cardinal motor signs of Parkinson's disease, alongside bradykinesia and resting tremor 13
• Have the patient relax completely while you passively move their limbs 12
• Test both upper and lower extremities, comparing sides for asymmetry 12
• Move the joint through its full range of motion at varying speeds 12
• Note any resistance to passive movement that remains constant throughout the range (lead-pipe rigidity) 12
• Look for "cogwheel" phenomenon - a ratchet-like, jerky resistance that occurs when rigidity is combined with tremor 12

Enhanced Testing Methods

• To enhance detection of subtle rigidity, ask the patient to perform an activation maneuver with the contralateral limb (e.g., opening and closing the opposite hand) while you test for rigidity 12
• This activation maneuver often brings out rigidity that might otherwise be difficult to detect 12
• Pay special attention to asymmetric rigidity, which may suggest corticobasal syndrome, especially when accompanied by alien hand phenomenon 12

Distinguishing Features from Other Parkinsonian Syndromes

• Asymmetric rigidity with alien hand phenomenon suggests Corticobasal Syndrome rather than idiopathic Parkinson's disease 12
• The presence of vertical gaze palsy (especially downward) alongside rigidity suggests Progressive Supranuclear Palsy 12
• Rigidity that affects the axial muscles more than limbs may suggest Multiple System Atrophy 13

Common Pitfalls to Avoid

• Failure to have the patient completely relax during testing can lead to false positives due to voluntary muscle contraction 12
• Not using activation maneuvers may cause you to miss subtle rigidity 12
• Confusing spasticity (velocity-dependent resistance that increases with faster stretching) with rigidity (constant resistance throughout movement) 12
• Remember that rigidity assessment is just one component of evaluating a patient with bradykinesia, and findings should be considered alongside other motor and non-motor symptoms for proper diagnosis and treatment planning 13

Assessment of Parkinson's Disease

Monitoring and Assessment

• Regular monitoring of nutritional and functional status throughout the disease course is essential, including body weight changes, vitamin status, dysphagia screening, and nutritional risk assessment, as 15% of community-dwelling PD patients are malnourished, and 24% are at medium-high risk 14
• The Unified Parkinson's Disease Rating Scale (UPDRS) is the standard clinical assessment tool for disease severity, consisting of four parts: mentation, activities of daily living, motor examination, and complications of therapy, with the Movement Disorder Society-UPDRS (MDS-UPDRS) being a newer version with improved evaluation of non-motor aspects, freezing of gait, and tremor subtypes 15

Diagnostic Confirmation and Management of Parkinson's Disease

Primary Diagnostic Responsibility

• General neurologists or movement disorder specialists should confirm the diagnosis of Parkinson's disease because correctly diagnosing a parkinsonian syndrome on clinical features alone can be quite challenging, as recommended by the American College of Radiology 16
• The coordinating physician role can be served by neurologists, paediatric neurologists, rehabilitation specialists, neurogeneticists, or primary-care physicians, but they must be aware of potential issues and able to access appropriate interventions, according to The Lancet Neurology 17

Diagnostic Confirmation Requirements

• Early severe autonomic dysfunction, cerebellar signs, or pyramidal signs suggest Multiple System Atrophy, as indicated by the Journal of the American College of Radiology 16

Role of Diagnostic Imaging

• I-123 ioflupane SPECT/CT (DaTscan) differentiates Parkinson's disease from essential tremor or drug-induced tremor, with a normal scan essentially excluding parkinsonian syndromes, as recommended by the American College of Radiology 16
• These imaging studies require proper interpretation in clinical context, another reason for neurologist involvement, according to the American College of Radiology 16

Common Pitfalls Without Specialist Involvement

• Missing atypical parkinsonian syndromes (PSP, MSA, CBD) that have different prognoses and treatment responses, as indicated by the American College of Radiology 16

Imaging Recommendations for Parkinsonism

Primary Imaging Modalities

• The American College of Radiology recommends I-123 ioflupane SPECT/CT as the gold standard nuclear medicine study for evaluating Parkinsonian syndromes because it differentiates true Parkinsonian syndromes from essential tremor and drug-induced tremor, demonstrates abnormality early in the disease course, and shows decreased radiotracer uptake in the striatum 18
• A normal I-123 ioflupane SPECT/CT essentially excludes Parkinsonian syndromes, according to the American College of Radiology 18

Role of FDG-PET/CT

• The American College of Radiology states that FDG-PET/CT has limited utility for initial Parkinsonian syndrome evaluation, with very limited good-quality evidence supporting its use 18
• FDG-PET/CT can help differentiate PSP from idiopathic PD by showing characteristic hypometabolism patterns, as recommended by the American College of Radiology 18

Structural Imaging

• The American College of Radiology recommends obtaining MRI brain without IV contrast as the optimal initial imaging modality before any nuclear medicine study, due to its superior soft-tissue characterization and sensitivity to iron deposition 18
• MRI brain without contrast rules out structural causes, focal lesions, or vascular disease, and is often normal in early PD but essential to exclude alternative diagnoses, according to the American College of Radiology 18

Critical Pitfalls to Avoid

• The American College of Radiology advises against ordering amyloid PET/CT, as there is no relevant literature supporting its use in Parkinsonian syndrome evaluation 18
• The American College of Radiology recommends against ordering tau PET/CT for initial Parkinsonian syndrome workup 19 20
• Skipping structural imaging is not recommended, as MRI is essential before functional imaging, according to the American College of Radiology 18

Diagnostic Workup for Early‑Onset Parkinsonism: Exclusion of Secondary Causes and Role of DAT‑SPECT

1. Systematic Exclusion of Secondary and Reversible Causes

• In adults presenting with early‑onset parkinsonism, clinicians must first rule out drug‑induced parkinsonism, Wilson’s disease, structural brain lesions, vascular disease, and metabolic disorders before labeling the condition as idiopathic Parkinson’s disease. 21

2. Wilson’s Disease Evaluation (Patients < 50 years)

• Wilson’s disease should be excluded in any patient under 50 years with parkinsonism by measuring serum ceruloplasmin, 24‑hour urinary copper excretion, and performing slit‑lamp examination for Kayser‑Fleischer rings. [22][23]
• Brain MRI may reveal the characteristic “face of the giant panda” sign or hyperintensities in the basal ganglia, thalamus, and brainstem, which are virtually pathognomonic for Wilson’s disease. 22
• Neurologic manifestations of Wilson’s disease include dystonia, increased muscle tone, rigidity, and tremor, mimicking Parkinsonian features. 22

3. Structural and Vascular Imaging

• MRI of the brain without contrast is mandatory to exclude structural lesions, vascular pathology, hydrocephalus, or focal abnormalities that could explain parkinsonism. 21
• Specific MRI findings that raise concern for vascular parkinsonism include multiple lacunar infarcts, diffuse white‑matter disease, or focal lesions in the basal ganglia. 21

4. Metabolic and Endocrine Screening

• Thyroid function tests (e.g., TSH, free T4) should be obtained to rule out hyperthyroidism as a reversible cause of parkinsonism. 23
• Assessment of calcium‑phosphorus metabolism and a non‑contrast brain CT are recommended to detect intracranial calcifications that may produce movement‑disorder symptoms. 23
• Blood glucose measurement is required to exclude diabetes‑related movement abnormalities. 23
• Serum bilirubin evaluation helps identify a remote history of kernicterus, which can present with basal‑ganglia injury. 23

5. Red‑Flag Clinical Features Suggesting Atypical Syndromes

• Early severe autonomic dysfunction, cerebellar signs, or pyramidal signs point toward Multiple System Atrophy rather than idiopathic Parkinson’s disease. 24
• Prominent vertical gaze palsy, especially downward, is indicative of Progressive Supranuclear Palsy. 24
• Asymmetric rigidity accompanied by an alien‑hand phenomenon raises suspicion for Corticobasal Syndrome. 24

6. DAT‑SPECT Imaging: Principles and Clinical Utility

• Dopamine‑Transporter SPECT (using I‑123 ioflupane) visualizes presynaptic dopamine terminals in the striatum, allowing differentiation of true dopamine‑deficient parkinsonian syndromes from mimics with intact dopaminergic function. 21
• The radiotracer binds specifically to dopamine transporters on presynaptic neurons; reduced striatal uptake indicates loss of nigrostriatal dopaminergic neurons, typically progressing from the posterior putamen to the anterior caudate. 21
• DAT‑SPECT is especially valuable when the clinical diagnosis is uncertain, helping to distinguish neurodegenerative parkinsonism from essential tremor, drug‑induced tremor, psychogenic parkinsonism, and dystonic tremors. 21
• A normal DAT‑SPECT essentially excludes dopamine‑deficient parkinsonian syndromes and identifies “subjects without evidence of dopamine deficiency” (SWEDDs). 21
• The technique can detect dopaminergic dysfunction early, even in presymptomatic or prodromal stages, before structural imaging shows abnormalities. 21

7. Recommended Imaging Algorithm for Early‑Onset Parkinsonism

8. Practical Pitfalls and Interpretation Guidance

• Never skip structural MRI before ordering functional imaging such as DAT‑SPECT; structural causes must be excluded first. 21
• DAT‑SPECT findings must be interpreted in the clinical context by a neurologist or movement‑disorder specialist; reduced DAT availability is supportive but not definitive for a specific neurodegenerative parkinsonian disorder. 21
• A normal DAT‑SPECT result is highly valuable for avoiding unnecessary dopaminergic therapy in patients whose symptoms are due to non‑degenerative causes. 21

I‑123 Ioflupane SPECT/CT (DaTscan) for the Evaluation of Parkinsonian Syndromes

Indications and Clinical Utility

• Use I‑123 ioflupane SPECT/CT in adults with unexplained bradykinesia, rigidity, or tremor when the clinical diagnosis remains uncertain after initial assessment. This nuclear brain scan is specifically recommended for differentiating true Parkinsonian syndromes from mimics such as essential tremor or drug‑induced parkinsonism. American College of Radiology 25

• The scan is abnormal in neurodegenerative Parkinsonian syndromes (PD, MSA, PSP, CBD) but normal in essential tremor, providing a reliable tool to distinguish these conditions. American College of Radiology 25, 26

• Drug‑induced parkinsonism typically yields a normal DaTscan, helping to separate medication‑related symptoms from true nigrostriatal degeneration. American College of Radiology 25, 27

Diagnostic Imaging Features

• I‑123 ioflupane binds to presynaptic dopamine transporters (DAT) in the striatum, allowing visualization of dopaminergic neuronal loss that characterizes Parkinson’s disease and related disorders. American College of Radiology 25, 26

• Characteristic pattern: decreased radiotracer uptake in the striatum progresses from posterior (putamen) to anterior (caudate) regions. American College of Radiology 25, 27, 28

• A normal DaTscan essentially excludes Parkinsonian syndromes, making it highly valuable for ruling out these conditions. American College of Radiology 25, 26

• Abnormal dopaminergic depletion can be detected early in the disease course, often before structural imaging (CT or MRI) shows any changes. American College of Radiology 25, 26

Limitations

• DaTscan cannot differentiate among specific Parkinsonian syndromes (e.g., PD vs. MSA vs. PSP vs. CBD); all present with abnormal dopaminergic depletion patterns. American College of Radiology 25

Alternative Nuclear Medicine Modalities

• FDG‑PET/CT can help discriminate Progressive Supranuclear Palsy (PSP) from idiopathic Parkinson’s disease by demonstrating characteristic hypometabolism in medial frontal and anterior cingulate cortices, striatum, and midbrain. American College of Radiology 25, 27

Specific Radiopharmaceutical for Dopamine Transporter (DAT) Imaging

Radiotracer Selection

• Clinical dopamine transporter scans employ I‑123 ioflupane (DaTscan), which binds exclusively to presynaptic dopamine transporters (DAT), whereas imaging of vesicular monoamine transporter‑2 (VMAT2) requires different radiotracers such as [¹¹C]PE2I; this distinction ensures that DAT scans specifically assess nigrostriatal dopaminergic neuronal integrity. [29] [30] 31